Cilostazol prevents retinal ischemic damage partly via inhibition of tumor necrosis factor-α-induced nuclear factor-kappa B/activator protein-1 signaling pathway

Pharmacology Research and Perspectives

Volumn 1, Issue 1, 2013, Pages

  Ishizuka, Fumiya ^a   Shimazawa, Masamitsu ^a   Egashira, Yusuke ^a,b   Ogishima, Hiromi ^a   Nakamura, Shinsuke ^a   Tsuruma, Kazuhiro ^a   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Activator protein 1; cilostazol; inflammation; nuclear factor kappa B; ocular ischemic syndrome; phosphodiesterase III inhibitor; retinal microvascular endothelial cells; tight junction proteins; tumor necrosis factor

Indexed keywords

EID: 85027830908     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.6     Document Type: Article

References (47)

1. Abcouwer SF, Lin CM, Wolpert EB, Shanmugam S, Schaefer EW, Freeman WM, et al. (2010). Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 51: 5920–5933.
2. Abe Y, Sekiya S, Yamasita T, Sendo F (1990). Vascular hyperpermeability induced by tumor necrosis factor and its augmentation by IL-1 and IFN-gamma is inhibited by selective depletion of neutrophils with a monoclonal antibody. J Immunol 145: 2902–2907.
3. Akula JD, Mocko JA, Moskowitz A, Hansen RM, Fulton AB (2007). The oscillatory potentials of the dark-adapted electroretinogram in retinopathy of prematurity. Invest Ophthalmol Vis Sci 48: 5788–5797.
4. Aveleira CA, Lin CM, Abcouwer SF, Ambrosio AF, Antonetti DA (2010). TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 59: 2872–2882.
5. Berger S, Savitz SI, Nijhawan S, Singh M, David J, Rosenbaum PS, et al. (2008). Deleterious role of TNF-alpha in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 49: 3605–3610.
6. Brown GC, Magargal LE (1988). The ocular ischemic syndrome. Clinical, fluorescein angiographic and carotid angiographic features. Int Ophthalmol 11: 239–251.
7. Chen D, Wei XT, Guan JH, Yuan JW, Peng YT, Song L, et al. (2012). Inhibition of c-Jun N-terminal kinase prevents blood-brain barrier disruption and normalizes the expression of tight junction proteins clautin-5 and ZO-1 in a rat model of subarachnoid hemorrhage. Acta Neurochir (Wien) 154: 1469–1476; discussion 1476.
8. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW (2002). Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300: 787–793.
9. Greenstein VC, Holopigian K, Hood DC, Seiple W, Carr RE (2000). The nature and extent of retinal dysfunction associated with diabetic macular edema. Invest Ophthalmol Vis Sci 41: 3643–3654.
10. Grozdanic SD, Sakaguchi DS, Kwon YH, Kardon RH, Sonea IM (2003). Functional characterization of retina and optic nerve after acute ocular ischemia in rats. Invest Ophthalmol Vis Sci 44: 2597–2605.
11. Guo S, Stins M, Ning M, Lo EH (2010). Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc Dis 30: 290–296.
12. Heynen H, Wachtmeister L, vanNorren D (1985). Origin of the oscillatory potentials in the primate retina. Vision Res 25: 1365–1373.
13. Horai S, Nakagawa S, Tanaka K, Morofuji Y, Couraud PO, Deli MA, et al. (2013). Cilostazol strengthens barrier integrity in brain endothelial cells. Cell Mol Neurobiol 33: 291–307.
14. Hotta H, Ito H, Kagitani F, Sato A (1998). Cilostazol, a selective cAMP phosphodiesterase inhibitor, dilates retinal arterioles and increases retinal and choroidal blood flow in rats. Eur J Pharmacol 344: 49–52.
15. Imai S, Inokuchi Y, Nakamura S, Tsuruma K, Shimazawa M, Hara H (2010). Systemic administration of a free radical scavenger, edaravone, protects against light-induced photoreceptor degeneration in the mouse retina. Eur J Pharmacol 642: 77–85.
16. Ishiguro M, Mishiro K, Fujiwara Y, Chen H, Izuta H, Tsuruma K, et al. (2010). Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS ONE 5: e15178.
17. Ishiguro M, Suzuki Y, Mishiro K, Kakino M, Tsuruma K, Shimazawa M, et al. (2011). Blockade of phosphodiesterase-III protects against oxygen-glucose deprivation in endothelial cells by upregulation of VE-cadherin. Curr Neurovasc Res 8: 86–94.
18. Ishizuka F, Shimazawa M, Umigai N, Ogishima H, Nakamura S, Tsuruma K, et al. (2013). Crocetin, a carotenoid derivative, inhibits retinal ischemic damage in mice. Eur J Pharmacol 703: 1–10.
19. Iwama D, Miyamoto K, Miyahara S, Tamura H, Tsujikawa A, Yamashiro K, et al. (2007). Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions. J Thromb Haemost 5: 818–825.
20. Jung WK, Lee DY, Park C, Choi YH, Choi I, Park SG, et al. (2010). Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases. Br J Pharmacol 159: 1274–1285.
21. Kashimoto R, Kurimoto T, Miyoshi T, Okamoto N, Tagami Y, Oono S, et al. (2008). Cilostazol promotes survival of axotomized retinal ganglion cells in adult rats. Neurosci Lett 436: 116–119.
22. Katsuno T, Umeda K, Matsui T, Hata M, Tamura A, Itoh M, et al. (2008). Deficiency of zonula occludens-1 causes embryonic lethal phenotype associated with defected yolk sac angiogenesis and apoptosis of embryonic cells. Mol Biol Cell 19: 2465–2475.
23. Kaur C, Foulds WS, Ling EA (2008). Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 27: 622–647.
24. Koto T, Takubo K, Ishida S, Shinoda H, Inoue M, Tsubota K, et al. (2007). Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol 170: 1389–1397.
25. Lee YJ, Eun JR (2012). Cilostazol decreases ethanol-mediated TNFalpha expression in RAW264.7 murine macrophage and in liver from binge drinking mice. Korean J Physiol Pharmacol 16: 131–138.
26. Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW (2008). Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury. CNS Neurosci Ther 14: 143–152.
27. Matsumoto M (2005). Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 6: 33–40.
28. Nakamura S, Imai S, Ogishima H, Tsuruma K, Shimazawa M, Hara H (2012). Morphological and functional changes in the retina after chronic oxygen-induced retinopathy. PLoS ONE 7: e32167.
29. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. (2003). Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161: 653–660.
30. Nonaka Y, Koumura A, Hyakkoku K, Shimazawa M, Yoshimura S, Iwama T, et al. (2009a). Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone. J Pharmacol Exp Ther 330: 13–22.
31. Nonaka Y, Tsuruma K, Shimazawa M, Yoshimura S, Iwama T, Hara H (2009b). Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage. Neurosci Lett 452: 156–161.
32. Ogishima H, Nakamura S, Nakanishi T, Imai S, Kakino M, Ishizuka F, et al. (2011). Ligation of the pterygopalatine and external carotid arteries induces ischemic damage in the murine retina. Invest Ophthalmol Vis Sci 52: 9710–9720.
33. Park SY, Lee SW, Baek SH, Lee CW, Lee WS, Rhim BY, et al. (2013). Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis. Br J Pharmacol 168: 1401–1411.
34. Rangaswamy NV, Zhou W, Harwerth RS, Frishman LJ (2006). Effect of experimental glaucoma in primates on oscillatory potentials of the slow-sequence mfERG. Invest Ophthalmol Vis Sci 47: 753–767.
35. Saishin Y, Saishin Y, Takahashi K, Melia M, Vinores SA, Campochiaro PA (2003). Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol 195: 210–219.
36. Shimazawa M, Hara H (2011). Novel situations of endothelial injury in stroke–mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke. J Pharmacol Sci 116: 30–35.
37. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. (2010). Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9: 959–968.
38. Stelzner TJ, Weil JV, O'Brien RF (1989). Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J Cell Physiol 139: 157–166.
39. Suzuki M, Harino S, Kitanishi K (1998). Effects of intravenous cilostazol on optic nerve head and choroidal blood flow in anesthetized cats. J Ocul Pharmacol Ther 14: 239–245.
40. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, et al. (1989). Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 20: 668–673.
41. Terelak-Borys B, Skonieczna K, Grabska-Liberek I (2012). Ocular ischemic syndrome – a systematic review. Med Sci Monit 18: RA138–RA144.
42. Torii H, Kubota H, Ishihara H, Suzuki M (2007). Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia/reoxygenation. Pharmacol Res 55: 104–110.
43. Umeda K, Ikenouchi J, Katahira-Tayama S, Furuse K, Sasaki H, Nakayama M, et al. (2006). ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 126: 741–754.
44. Wachtmeister L (1998). Oscillatory potentials in the retina: what do they reveal. Prog Retin Eye Res 17: 485–521.
45. Yoshida H, Ashikawa Y, Itoh S, Nakagawa T, Asanuma A, Tanabe S, et al. (2012). K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model. PLoS ONE 7: e46432.
46. Zhang SX, Ma JX, Sima J, Chen Y, Hu MS, Ottlecz A, et al. (2005). Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy. Am J Pathol 166: 313–321.
47. Zhang C, Guo Y, Miller NR, Bernstein SL (2009). Optic nerve infarction and post-ischemic inflammation in the rodent model of anterior ischemic optic neuropathy (rAION). Brain Res 1264: 67–75.